Last year, the firm saw 21 percent growth in reproductive health, 56 percent growth in oncology, and 49 percent growth in infectious disease testing.
The companies signed an agreement earlier this year to jointly develop microbiome research services for international markets including a shotgun metagenomic sequencing-based service.
The Singapore-based firm plans to use its single-cell RNA and protein assay to help optimize the production of CAR T cells and guide their use in patients.
The researchers were able to engineer variants of the base editors that reduced the off-target RNA SNVs while maintaining their on-target DNA editing.
A few key loci appear to contribute to a lasting immune response following childhood immunizations against meningococcal bacteria, tetanus, or Haemophilus influenzae type B.
In PNAS this week: diversity and spread of Yersinia pestis, local adaptations in switchgrass, and more.
China's State Council is strengthening regulations regarding scientific studies that rely on genetic or other material from Chinese individuals, according to Reuters.
Biotage will provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand.
In PNAS this week: plant protein engineering, Angelman syndrome, and more.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.